ZA200502858B - Controlled releases system containing temozolomide - Google Patents
Controlled releases system containing temozolomide Download PDFInfo
- Publication number
- ZA200502858B ZA200502858B ZA200502858A ZA200502858A ZA200502858B ZA 200502858 B ZA200502858 B ZA 200502858B ZA 200502858 A ZA200502858 A ZA 200502858A ZA 200502858 A ZA200502858 A ZA 200502858A ZA 200502858 B ZA200502858 B ZA 200502858B
- Authority
- ZA
- South Africa
- Prior art keywords
- polymeric materials
- temozolomide
- controlled release
- temolozomide
- microspheres
- Prior art date
Links
- 229960004964 temozolomide Drugs 0.000 title claims description 71
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 title claims description 70
- 238000013270 controlled release Methods 0.000 title claims description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 60
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 56
- 239000000463 material Substances 0.000 claims description 36
- 239000004005 microsphere Substances 0.000 claims description 33
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 18
- -1 polyethylene Polymers 0.000 claims description 18
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000839 emulsion Substances 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- 150000008064 anhydrides Chemical class 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- QMMOXUPEWRXHJS-UHFFFAOYSA-N pent-2-ene Chemical compound CCC=CC QMMOXUPEWRXHJS-UHFFFAOYSA-N 0.000 claims description 4
- 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 229920000265 Polyparaphenylene Polymers 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 3
- 229920002492 poly(sulfone) Polymers 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 3
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 3
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000013557 residual solvent Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000007943 implant Substances 0.000 description 53
- 239000003826 tablet Substances 0.000 description 39
- 239000000243 solution Substances 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 8
- 229910052782 aluminium Inorganic materials 0.000 description 8
- 230000005251 gamma ray Effects 0.000 description 8
- 239000002650 laminated plastic Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229920002732 Polyanhydride Polymers 0.000 description 5
- 239000004623 biodegradable polyanhydride Substances 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000003733 ovarian melanoma Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02131347 | 2002-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200502858B true ZA200502858B (en) | 2008-01-30 |
Family
ID=32034727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200502858A ZA200502858B (en) | 2002-09-29 | 2005-04-08 | Controlled releases system containing temozolomide |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8821913B2 (ru) |
| EP (1) | EP1550444A4 (ru) |
| JP (1) | JP4879488B2 (ru) |
| KR (1) | KR100979217B1 (ru) |
| CN (1) | CN100366249C (ru) |
| AU (1) | AU2003272857B2 (ru) |
| BR (1) | BR0314838A (ru) |
| CA (1) | CA2500387C (ru) |
| MX (1) | MXPA05003315A (ru) |
| NZ (1) | NZ539527A (ru) |
| PL (1) | PL218200B1 (ru) |
| RU (1) | RU2322979C2 (ru) |
| UA (1) | UA87813C2 (ru) |
| WO (1) | WO2004028534A1 (ru) |
| ZA (1) | ZA200502858B (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100431608C (zh) * | 2005-04-06 | 2008-11-12 | 山东蓝金生物工程有限公司 | 一种含四嗪类化合物的抗实体肿瘤药物组合物 |
| CN101559037B (zh) * | 2008-04-16 | 2013-01-30 | 北京京卫燕康药物研究所有限公司 | 用于静脉和脑内注射的两元溶液型制剂 |
| US9316632B2 (en) * | 2009-03-17 | 2016-04-19 | Marshall University Research Corporation | Methods of screening chemotherapeutic agents and treating cancer |
| WO2010144881A1 (en) * | 2009-06-12 | 2010-12-16 | The General Hospital Corporation | Treatment of meningeal and neural diseases |
| CN101869551B (zh) * | 2010-06-28 | 2012-04-18 | 江苏奥赛康药业股份有限公司 | 一种替莫唑胺冻干制剂 |
| CN102406627B (zh) * | 2011-11-22 | 2013-03-13 | 温州医学院 | 一种层层组装马赛克结构药物缓释植片 |
| CN104324014A (zh) * | 2014-11-25 | 2015-02-04 | 深圳市健元医药科技有限公司 | 一种含醋酸卡泊芬净的药物组合物缓释植入剂及其制备 |
| US9956172B2 (en) | 2015-07-28 | 2018-05-01 | Board Of Regents, The University Of Texas System | Implant compositions for the unidirectional delivery of therapeutic compounds to the brain |
| CN108403656A (zh) * | 2018-04-03 | 2018-08-17 | 孙奉生 | 一种用于治疗多形性胶质母细胞瘤的替莫唑胺多晶型胶囊 |
| US20200129435A1 (en) * | 2018-10-24 | 2020-04-30 | Uvic Industry Partnerships Inc. | Composition for delivering a therapeutic agent and methods for making and using |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888176A (en) * | 1984-05-21 | 1989-12-19 | Massachusetts Institute Of Technology | Controlled drug delivery high molecular weight polyanhydrides |
| US4757128A (en) * | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
| US5633000A (en) | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| DE19608423A1 (de) * | 1996-03-05 | 1997-09-11 | Merck Patent Gmbh | Implantate mit phasenweiser Arzneistoffabgabe |
| AU9376998A (en) * | 1997-09-02 | 1999-03-22 | Johns Hopkins University School Of Medicine, The | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
| BR0009380A (pt) * | 1999-03-30 | 2001-12-26 | Schering Corp | Tratamento de câncer melhorado comtemozolomida |
| SE9903236D0 (sv) * | 1999-09-10 | 1999-09-10 | Astra Ab | Method to obtain microparticles |
| JP4144980B2 (ja) * | 1999-09-22 | 2008-09-03 | オリンパス株式会社 | ステージ装置 |
| US6647412B1 (en) | 2000-06-23 | 2003-11-11 | Nokia Internet Communications Inc. | Method and network for propagating status information |
| EP1317304B1 (en) * | 2000-09-01 | 2011-04-27 | Palmaya Pty Ltd. | Slow release pharmaceutical preparation and method of administering same |
| US20020128228A1 (en) * | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
-
2003
- 2003-09-26 CN CNB031348521A patent/CN100366249C/zh not_active Expired - Lifetime
- 2003-09-29 CA CA2500387A patent/CA2500387C/en not_active Expired - Fee Related
- 2003-09-29 JP JP2004538664A patent/JP4879488B2/ja not_active Expired - Fee Related
- 2003-09-29 WO PCT/CN2003/000838 patent/WO2004028534A1/zh active Application Filing
- 2003-09-29 NZ NZ539527A patent/NZ539527A/en not_active IP Right Cessation
- 2003-09-29 KR KR1020057005432A patent/KR100979217B1/ko active IP Right Grant
- 2003-09-29 UA UAA200504086A patent/UA87813C2/ru unknown
- 2003-09-29 EP EP03753238A patent/EP1550444A4/en not_active Withdrawn
- 2003-09-29 BR BR0314838-6A patent/BR0314838A/pt not_active Application Discontinuation
- 2003-09-29 US US10/529,454 patent/US8821913B2/en not_active Expired - Fee Related
- 2003-09-29 RU RU2005113282/15A patent/RU2322979C2/ru active
- 2003-09-29 PL PL376130A patent/PL218200B1/pl unknown
- 2003-09-29 MX MXPA05003315A patent/MXPA05003315A/es active IP Right Grant
- 2003-09-29 AU AU2003272857A patent/AU2003272857B2/en not_active Ceased
-
2005
- 2005-04-08 ZA ZA200502858A patent/ZA200502858B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006504698A (ja) | 2006-02-09 |
| CA2500387A1 (en) | 2004-04-08 |
| EP1550444A4 (en) | 2010-05-26 |
| US8821913B2 (en) | 2014-09-02 |
| KR20050072094A (ko) | 2005-07-08 |
| BR0314838A (pt) | 2005-08-09 |
| JP4879488B2 (ja) | 2012-02-22 |
| AU2003272857B2 (en) | 2008-08-07 |
| US20050244494A1 (en) | 2005-11-03 |
| RU2322979C2 (ru) | 2008-04-27 |
| RU2005113282A (ru) | 2005-10-10 |
| WO2004028534A1 (en) | 2004-04-08 |
| CA2500387C (en) | 2012-07-10 |
| EP1550444A1 (en) | 2005-07-06 |
| UA87813C2 (ru) | 2009-08-25 |
| MXPA05003315A (es) | 2005-10-18 |
| NZ539527A (en) | 2007-10-26 |
| AU2003272857A1 (en) | 2004-04-19 |
| CN100366249C (zh) | 2008-02-06 |
| PL218200B1 (pl) | 2014-10-31 |
| KR100979217B1 (ko) | 2010-08-31 |
| CN1600307A (zh) | 2005-03-30 |
| PL376130A1 (en) | 2005-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200502858B (en) | Controlled releases system containing temozolomide | |
| US8741317B2 (en) | Slow-degrading polymers comprising salicylic acid for undelayed and sustained drug delivery | |
| CN110062628A (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| CN101219113A (zh) | 含苯达莫司汀的复方抗癌缓释注射剂 | |
| CN111565714B (zh) | 包含依维莫司的实现稳定化的药剂学制剂 | |
| CN101254169A (zh) | 含抗结核病药物的缓释剂 | |
| KR20120098906A (ko) | 서방성 제제 | |
| CN1332668C (zh) | 千金藤素缓释制剂 | |
| CN100998555A (zh) | 一种含血管抑制剂的抗癌缓释剂 | |
| MX2012014265A (es) | Formulacion de liberacion sostenida. | |
| CN101219112A (zh) | 一种含苯达莫司汀的复方抗癌缓释注射剂 | |
| CN101283971A (zh) | 一种含抗生素林可霉素的缓释注射剂及其应用 | |
| CN100998558A (zh) | 一种同载卡莫司汀和氟尿嘧啶的抗癌缓释剂 | |
| GB2612779A (en) | Pharmaceutical formulation comprising Tacrolimus, method for the preparation thereof and use | |
| WO2022097024A1 (en) | Pharmaceutical composition comprising meloxicam | |
| CN101023919A (zh) | 一种抗实体肿瘤缓释剂 | |
| CN100998591A (zh) | 含埃坡霉素和血管抑制剂的抗癌组合物 | |
| CN101278910A (zh) | 一种含抗生素强力霉素的缓释注射剂及其应用 | |
| CN101278911A (zh) | 一种含抗生素沙氟沙星的缓释注射剂及其应用 | |
| CN101283970A (zh) | 一种含抗生素的缓释注射剂及其应用 | |
| JPH06234656A (ja) | ペプチド含有徐放性製剤およびその製造法 | |
| CN101278909A (zh) | 一种含抗生素达氟沙星的缓释注射剂及其应用 | |
| CN101023924A (zh) | 一种含糖皮质激素的抗实体肿瘤缓释剂 | |
| CN101301272A (zh) | 一种含美洛西林的缓释剂及其应用 | |
| CN101283972A (zh) | 一种含抗生素泰洛星的缓释注射剂及其应用 |